Background: Most pathogenic mutations in the BRCA2 gene carry a high risk of hereditary breast and ovarian cancer (HBOC). However, a stop-gain mutation, K3326* (rs11571833), confers risk of lung cancer and cancers of the upper-aero-digestive tract but only a modest risk of breast or ovarian cancer. The Icelandic population provides an opportunity for comprehensive characterization of the cancer risk profiles of K3326* and HBOC mutations because a single mutation, BRCA2 999del5, is responsible for almost all BRCA2-related HBOC in the population. Methods: Genotype information on 43 641 cancer patients and 370 971 control subjects from Iceland, the Netherlands, and the United States was used to assess the cancer risk profiles of K3326* and BRCA2 999del5. BRCA2 expression was assessed using RNAseq data from blood (n ¼ 2233), as well as 52 tissues reported in the GTEx database. Results: The cancer risks associated with K3326* are fundamentally different from those associated with 999del5. We report for the first time an association between K3326* and small cell lung cancer (odds ratio [OR] ¼ 2.06, 95% confidence interval [CI] ¼ 1.35 to 3.16) and squamous cell carcinoma of the skin (OR ¼ 1.69, 95% CI ¼ 1.26 to 2.26). Individuals homozygous for K3326* reach old age and have children. Unlike BRCA2 999del5, the K3326* allele does not affect the level of BRCA2 transcripts, and the allele is expressed to the same extent as the wild-type allele. Conclusions: K3326* associates primarily with cancers that have strong environmental genotoxic risk factors. Expression of the K3326* allele suggests that a variant protein may be made that retains the DNA repair capabilities important to hormoneresponsive tissues but may be less efficient in responding to genotoxic stress.
Pathogenic mutations in BRCA2 predispose to hereditary breast and ovarian cancer (HBOC) syndrome, characterized by greatly increased risk of cancers of the breast and ovary as well as other cancers (1) . However, HBOC-associated mutations do not increase risk of lung cancer, suggesting that lung epithelium may be less dependent on BRCA2 function than the tissues involved in HBOC. It was therefore unexpected when a stop-gain variant close to the 3' end of the BRCA2 gene, rs11571833 (NM_000059.3:c.9976A>T; NP_000050.2:p.Lys3326Ter, hereafter referred to as K3326*), was reported to confer risk of lung cancer (2) . Analysis of 21 594 lung cancer patients and 54 156 control subjects of European origin found that carriers of the variant had an odds ratio (OR) of 1.83 (95% confidence interval [CI] ¼ 1.61 to 2.09) of developing the disease (2) . The same study also showed that the association was stronger with squamous cell lung carcinoma (SQLC) than adenocarcinoma of the lung (OR ¼ 2.47, 95% CI ¼ 2.03 to 3.00; OR ¼ 1.47, 95% CI ¼ 1.19 to 1.82, respectively). K3326* is located in the last of the 27 exons of the BRCA2 gene and is predicted to result in the loss of the 93 C-terminal amino acids of the protein product. In addition to its association with lung cancer risk, K3326* associates with substantial risk of cancers of the upper aero-digestive tract (UADT; OR ¼ 2.53, 95% CI ¼ 1.89 to 3.38) (3) and esophageal squamous cell carcinoma (OR ¼ 6.0, 95% CI ¼ 1.3 to 28) (4) .
Unlike variants in BRCA2 that associate with HBOC, the K3326* variant has a small effect on hormone-related cancers (5, 6) . A recent study including 76 637 cancer patients and 83 796 control subjects showed a modest increase in risk of breast cancer (OR ¼ 1.28, 95% CI ¼ 1.17 to 1.40) and invasive ovarian cancer (OR ¼ 1.26, 95% CI ¼ 1.10 to 1.43) (6) . No association with prostate cancer was observed. Finally, K3326* was reported to be more common in familial pancreatic cancer patients than in control subjects (144 cancer patients and 250 control subjects, OR ¼ 4.84, 95% CI ¼ 1.27 to 18.55) (7) .
The difference between the cancer risk profiles of K3326* and variants in BRCA2 that associate with HBOC could provide insights into how the roles of BRCA2 differ between tissues. However, dissection of this phenomenon is complicated because rare pathogenic mutations may reside on the background of K3326*, affecting the risk estimates for the variant. The Icelandic population is ideally suited to the characterization of cancer risk and clinical presentation of K3326*. This is because a single founder mutation in BRCA2, commonly referred to as 999del5 (rs80359671, NM_000059.3:c.767_771delCAAAT, NP_000050.2:p. Asn257Lysfs), is responsible for virtually all BRCA2-related HBOC in the population, and this mutation is never on the same chromosome as K3326* (2). Here, we combined extensive information on genetic variation in the Icelandic population with data from the nation-wide cancer registry in order to compare the cancer risk profiles of K3326* and HBOC mutations.
Methods
This study used genotype information on a total of 43 641 cancer patients and 370 971 control subjects from Iceland, the Netherlands, and the United States. An in-depth description of the study populations and methods is presented in the Supplementary Methods (available online).
Icelandic Study Population
This study is based on extensive genetic information on the Icelandic population, which has been previously described (8) .
The whole genomes of 15 220 Icelanders were sequenced, unveiling 40 780 213 single nucleotide polymorphisms (SNP) and short indels. These variants were imputed into 151 677 Icelanders whose DNA had been genotyped with various Illumina SNP chips and phased using long-range phasing (9, 10) . Genealogical deduction of carrier status of 282 894 untyped relatives of chip-typed individuals further increased the sample size for association analysis. Information on cancer in the genotyped individuals is from the population-based Icelandic Cancer Registry (ICR) (11) . A total of 42 331 Icelandic cancer patients and 354 488 control subjects were used in the analysis. With the aid of hospital charts, 53 genotyped lung cancer K3326* carriers diagnosed in the years 2000-2015 were staged according to the International Association for the Study of Lung Cancer 7th edition of TNM staging. These were compared with the stages of all 155 lung cancer patients diagnosed in 2009 in Iceland.
The study was approved by the National Bioethics Committee of Iceland (ref. 12-122-V7). Written informed consent was obtained from all genotyped subjects.
Statistical Analysis
Association results for the BRCA2 variants tested in the Icelandic cancer patients come from genome-wide association studies (GWAS) on the 20 cancers. The methods used for association testing in the Icelandic population have been described in detail (12) . To test for association between SNPs and cancer in the Icelandic study, logistic regression was used, treating disease status as the response and genotype counts as covariates. Other relevant covariates that might correlate with disease status were also included in the model as nuisance, for example, sex, county of birth, current age or age at death (first-and second-order terms included), blood sample availability for the individual, and an indicator function for the overlap of the lifetime of the individual with the time span of phenotype collection. To account for inflation in test statistics due to cryptic relatedness and stratification in the Icelandic population, we applied the method of linkage disequilibrium (LD) score regression (13) . With a set of 1.1 M variants, we regressed the v 2 statistics from our GWAS scan against LD score and used the intercept as a correction factor. The LD scores were downloaded from an LD score database (see the URL in the "Notes"), and the estimated correction factors are listed in Supplementary Table 1 (available online). All statistical tests were two-sided, and a P value of less than .05 was considered statistically significant unless otherwise noted.
UADT Cancer Patients and Control Subjects
In total, 696 head and neck cancers and 119 squamous cell esophageal carcinomas were collected in two studies (14, 15) . Information on the ICD codes for the UADT populations used and referred to can be found in Supplementary Table 2 (available online). The 4139 Dutch control subjects were from the Nijmegen Biomedical Study (16) . The protocols of all the studies were approved by the respective institutional review boards, and all study subjects gave written informed consent. In the UADT cancer patients and control subjects, the rs11571833 (K3326*) variant was genotyped using the Centaurus (Nanogen) platform (17) . The c.6275delTT and c.4889C>G mutations were genotyped by Sanger sequencing. Primer sequences are listed in Supplementary Table 3 (available online).
Squamous Cell Skin Cancer Patients and Control Subjects
Association results for squamous cell skin cancer (SQCSC) and the BRCA2 variants were looked up in two GWAS studies, one from Rotterdam and the other from Ohio.
The Rotterdam Study
The Rotterdam Study (RS) is a prospective population-based follow-up study of the determinants and prognosis of chronic diseases in the middle age and elderly participants living in the Ommoord district (Rotterdam, the Netherlands) (18) . The Medical Ethics Committee of the Erasmus Medical Center and the review board of the Dutch Ministry of Health, Welfare and Sports have ratified the RS. Written informed consent was obtained from all participants. Details on the ascertainment of skin cancer in the RS is presented elsewhere (19) . Briefly, all RS participants with informed consent (n ¼ 14 628) were linked to the nationwide registry of histo-and cytopathology in the Netherlands (PALGA; up to December 31, 2013). All prevalent SQCSCs were labeled as patients. Participants from the RS without PALGA reports were considered control subjects. Cohorts RS-I and RS-II were genotyped with the Infinium II HumanHap550K Genotyping BeadChip version 3 (Illumina, San Diego, CA), and the cohort RS-III was genotyped using the Illumina Human 610 Quad Arrays. The three data sets were aligned to the same strand as the GoNL data set (20) and restricted to a common set of 452 673 autosomal variants. Variants with a minor allele frequency of less than 0.5% (nine variants) that fail (P < 1e-7) the Hardy-Weinberg test and that have statistically significant differences (P < 1e-6) in frequency between data sets were excluded. The resulting genotypes for 450 395 variants were phased using SHAPEIT (v2.790) (21) . Imputation was done with IMPUTE2 (v2.3.2) (22), using the GoNL data set as reference (https://molgenis26.target.rug.nl/downloads/gonl_public/variants/release5/) (20) . A logistic casecontrol study GWAS was carried out on 398 SQCSC patients and 10 629 control subjects of Dutch origin, using SNPTEST (v2.5.2) (23) with a frequentist (additive) and expected dosage as main parameters. The model was adjusted for age at the start of the study, sex, and four principal components. Further quality control of the GWAS results included the removal of markers with low imputation quality (R 2 < 0.3), duplicated markers, and markers with high betas or standard errors (larger than 10), using EasyQC (24) . The rs11571833 (K3326*) variant is not present in GoNL. Therefore, we used rs11571815, which is fully correlated with rs11571833 (R 2 ¼ 1) in Northern Europeans from Utah (CEU) and Iceland as a proxy.
The Ohio Study
This study was approved by the Ohio State University Institutional Review Board. All study participants signed informed consent. Genomic DNA was collected from 103 SQCSC patients ascertained from dermatology clinics. Control subjects (n ¼ 1715) were obtained from the Columbus area control study and were individuals without a self-reported SQCSC diagnosis and were matched to the population and banked patients by sex and age of diagnosis. Samples were genotyped on Illumina chips as described above, phased using SHAPEIT (v2.790), and imputed using 1000 Genomes Phase 3 (October 2014) as a reference set.
Test for Heterogeneity Between the Different Populations
The results for the multiple case-control groups were combined using a fixed-effects inverse variance method based on effect estimates and standard errors (Supplementary Methods, available online) (25) .
RNA Analysis
Preparation of poly(A) þ cDNA sequencing libraries and RNA sequencing were carried out as described previously (26) . A detailed protocol for the RNA analysis is presented in the Supplementary Methods (available online).
Results
To compare the cancer risks associated with K3326* and 999del5, we tested the associations between the variants and 20 cancer types ( Table 1) . As expected, very strong associations were observed between 999del5 and cancers of the breast, ovary, prostate, and pancreas. In addition, squamous UADT cancers showed statistically significant association with 999del5 (20 tests, statistical significance threshold of
). Several cancer types show suggestive association with 999del5, that is, SQCSC and cancers of the stomach, urinary bladder, and cervix. When all cancers are combined, the risk of 999del5 carriers being diagnosed with some form of cancer is more than fourfold that of the general population. We observed no statistically significant association between lung cancer and 999del5 (OR ¼ ), whereas no association to adenocarcinoma was detected in our sample set (OR ¼ 0.98, 95% CI ¼ 0.66 to 1.45, P ¼ .92). The associations of K3326* with SCLC and SQCSC have not been reported before.
To refine our estimate of the association of K3326* with SQCSC, we genotyped the variant in two additional SQCSC sample sets from the Netherlands and the United States ( , 366 patients, 186 714 control subjects). However, contrary to previous reports (3, 4) , there was no statistically significant association observed between UADT cancers and K3326* in Iceland. To exclude systematic errors in the registration of this cancer group, a pathology review was performed on a random set of 30 samples from different periods. The pathology review confirmed the diagnoses of all 30 samples. In line with published results, we observed a strong association of K3326* with UADT cancers in samples from the Netherlands (OR ¼ 2.68, 95% CI ¼ 1.67 to 4.31, P ¼ 5.0 Â 10 -5 ) ( Table 2 ). Comparing the distribution of cancer sites between the Icelandic and Dutch UATD cancer patients, we note a higher fraction of oral cavity cancer in the Icelandic patients and a higher fraction of cancers ARTICLE of the oropharynx and hypopharynx in the Dutch patients (Supplementary Table 4 , available online). However, this difference does not explain the difference in cancer risk between the populations because K3326* is associated with risk of all subtypes of UADT cancers in our Dutch data set (Supplementary Table 5 , available online) as well as in the published report (3) . Previous studies of families with breast cancer of northern European ancestry show that two rare mutations, BRCA2 c.6275delTT and c.4889C>G, which are highly penetrant for breast and ovarian cancer, occur on the K3326* haplotype (27) . ) , as well as for the three most common histological subtypes of lung cancer. Odds ratios are based on population control subjects. CI ¼ confidence interval; MAF ¼ minor allele frequency; MGUS ¼ monoclonal gammopathy of undetermined significance; OR ¼ odds ratio. ‡The numbers of cancer patients (N aff ) and control subjects (N controls ) correspond to the number of individuals used in the association tests. §The association was tested using logistic regression, and results for the multiple case-control groups were combined using a fixed-effects inverse variance method based on effect estimates and standard errors. Heterogeneity in the effect estimate was tested using a Cochran's Q test statistic. All P values reported are two-sided. kThe odds ratios correspond to minor alleles. ¶Results that remain statistically significant after correction for number of tests. .02 82.4 †The association was tested using logistic regression, and results for the multiple case-control groups were combined using a fixed-effects inverse variance method based on effect estimates and standard errors. Heterogeneity in the effect estimate was tested using a Cochran's Q test statistic. All P values reported are two-sided.
Odds ratios are based on population control subjects. CI ¼ confidence interval; MAF ¼ minor allele frequency; OR ¼ odds ratio; SQCSC ¼ squamous cell skin cancer;
UADT ¼ upper aero-digestive tract. ‡Imputation information for marker estimated by the ratio of the variance of imputed expected allele counts and the variance of the actual allele counts. §The variant rs11571815 was used as a surrogate for rs1157833 (K3326* variant) in the Dutch SQCSC population because the GoNL data set does not contain rs1157833.
The two variants are fully correlated in CEU (R2 ¼ 1). krs1157833 was directly genotyped in the Dutch UADT patients and control subjects.
These mutations have not been found in Iceland. However, the BRCA2 c.6275delTT mutation has been found in several HBOC families in the Netherlands (28) , prompting speculations that these mutations could be responsible for the UADT signal, rather than the K3326* variant in the Dutch population. We genotyped the c.6275delTT and c.4889C>G mutations in the Dutch UADT cancer sample set using Sanger sequencing (Supplementary Table 6 , available online). Neither mutation was found, suggesting that the K3326* variant alone explains the association with UADT cancer in the Netherlands.
Carriers of HBOC mutations in BRCA2 are on average diagnosed with breast, ovarian, and prostate cancers at a younger age than noncarriers (29) (30) (31) . The K3326* variant did not affect the age at diagnosis for lung cancer (Supplementary Table 7 , available online). When considering the whole Icelandic population, carriers of K3326* have a slightly shorter lifespan than noncarriers among deceased individuals who lived to be age 50 years and were born after 1890 (P ¼ .01, b ¼ -0.063, n ¼ 118 626). Considering lung cancer patients only, the ratio of males to females among carriers of K3326* was not statistically significantly different from the ratio of males to females with lung cancer in the total cancer registry (55.5% vs 51.9%, P ¼ .54).
Bi-allelic mutations in BRCA2 result in Fanconi anemia (FA) complementation group D1 (FA-D1) (32), a chromosome instability disorder that causes childhood-onset aplastic anemia and cellular hypersensitivity to DNA crosslinking agents, as well as a strong cancer predisposition. Although the cancer risk profile of the K3326* mutation is more modest than that of the HBOC mutations, it is possible that homozygosity for the variant could have consequences over and beyond a multiplicative risk for the cancers observed in heterozygotes. In total, 17 homozygous individuals were observed in our population of 151 677 chiptyped Icelanders; this is in agreement with the expectation under the Hardy-Weinberg equilibrium (17 expected), given the allelic frequency of 1.1% for K3326*. Homozygous individuals reach adulthood (oldest 92 years) and have children (Table 3) . Information on cancer in the 17 K3326* homozygotes, as well as the seven compound K3326*/999del5 heterozygous carriers observed, is listed in Table 3 . No homozygotes for the 999del5 mutation were observed in 151 677 chip-typed individuals (expected to be two under the Hardy-Weinberg equilibrium and allelic frequency of 0.36%).
We tested if the stage distribution of carriers of K3326* was different from noncarriers. Because disease stage is not registered in the ICR, we retrieved the medical records and registered the stage of disease of all 53 carriers of K3326* diagnosed with LC in the years 2000-2015 as well as all 155 LC patients diagnosed in the year 2009 for comparison. We found no difference in the stage distribution between carriers and noncarriers with NSCLC (Supplementary Table 8 , available online).
The effect of K3326* on the function of the BRCA2 protein in different tissues remains to be determined. As the variant introduces a stop codon in the last exon of the gene, the mRNA will likely escape nonsense-mediated decay (NMD), allowing translation of a truncated protein product (33) . To assess the effects of the K3326* and 999del5 variants on transcript levels, BRCA2 mRNA was assessed in RNA-Seq data from the blood of individuals with wild-type BRCA2 (n ¼ 2181), individuals heterozygous for K3326* (n ¼ 40), and individuals homozygous for K3326* (n ¼ 2), as well as individuals heterozygous for 999del5 (n ¼ 10). As previously reported (34) , heterozygous carriers of the 999del5 mutation have fewer BRCA2 transcripts than noncarriers, in line with 999del5 inducing NMD (Figure 1 ). In contrast, carriers of K3326* express normal levels of BRCA2 mRNA, and no allelic imbalance in expression was detected for heterozygous individuals (87 reference vs 90 alternative total number of fragments). This indicates that transcripts carrying the K3326* are not subjected to NMD and that a truncated BRCA2 protein may be generated. Similarly, using data from GTEx, K3326* was not found to affect BRCA2 transcript levels in other tissues, such as lung (Supplementary Figure 1, available online) , sun-exposed skin, subcutaneous adipose tissue, thyroid, or whole blood (Supplementary Table 9 , available online).
Discussion
Here, we used the comprehensive information on genetic variation in the Icelandic population, along with information on 49 051 diagnoses of 20 different cancers to dissect and compare the cancer risks of the K3326* variant and the 999del5 founder mutation that behaves like a typical HBOC mutation. We confirm the previously reported associations with total LC and SQLC. In addition, we demonstrate associations with SCLC and SQCSC not previously reported.
The reported association between K3326* and UADT cancer was not replicated in the Icelandic population, although a strong effect of the 999del variant on this cancer group was observed. Possible explanations of the difference in UADT cancer risk between Iceland and the other populations include different etiological factors, such as infection with human papilloma virus (HPV). HPV associates most strongly with oropharyngeal cancers, and this cancer subtype is less common in the Icelandic population than in the Dutch data set used here. However, K3326* was previously reported to associate with all subtypes of UADT cancers (oral cavity, oropharynx, larynx/hypopharynx, and esophagus) (3), and these associations are replicated in our Dutch sample set. In the Icelandic UADT cancer group, the strongest effect of K3326* (albeit statistically nonsignificant) was with oropharyngeal cancer.
It is of interest that K3326* associates with cancer types that have strong environmental genotoxic risk factors, that is, smoking for SQLC, SCLC and UADT cancer, and ultraviolet (UV) radiation for SQCSC. This suggests that the DNA repair capability of the truncated BRCA2 protein may be impaired, rendering affected individuals more vulnerable to genotoxic stress. BRCA2 has two well-characterized roles in the maintenance of genomic integrity, homology-directed repair (HDR) of double-strand breaks (35) and a role in preventing degradation of stalled replication forks (36) . In both cases, the function of BRCA2 is dependent on the interaction with RAD51. The RAD51 interaction domain needed to stabilize stalled replication forks is located between amino acids 3270 and 3305 in exon 27 (37) , in close proximity to K3326*, prompting speculations that the truncation might interfere with the interaction between RAD51 and the Cterminus of BRCA2. This would affect the ability of BRCA2 to prevent the MRE11-mediated degradation of stalled replication forks, resulting in genomic instability and increased cancer risk. Such a defect would be more likely to have a biological impact under stressful conditions where replication fork progression is constantly being challenged, for instance, in the presence of bulky DNA adducts caused by frequent exposure to carcinogenic agents such as tobacco smoke or UV light. On the contrary, studies have shown that the BRCA2 C-terminus RAD51 interaction domain is dispensable for HDR repair (36) , which may explain why the K3326* variant does not have a strong effect on breast or ovarian cancer risks. Our population-based assessment of the 999del5 founder mutation highlights the complexity of cancer risks conferred by loss-of-function mutations in BRCA2. Current evidence suggests that other cancer susceptibility genes, many of which have a role in DNA repair, also have complex risk patterns that still need to be characterized in full (38) . Dissection of the risk patterns of these genes is likely to have important implications for the genetic counseling of mutation carriers, which has historically been strongly focused on a limited number of cancer types.
The limitation of this study lies in the lack of power for rare cancer types. Additional studies with more patients will provide more robust estimates of the risk for these cancer types. Also, due to the low frequency of the K3326* variant, it was not possible to test if the variant affects survival of lung cancer patients.
In conclusion, our study shows that the K3326* variant in BRCA2 associates primarily with cancer types that have strong environmental genotoxic risk factors. We report for the first time an association between the variant and risk of SCLC and SQCSC. The risk profile of K3326* suggests that while the variant protein retains the ability to maintain genomic stability in hormone-related tissues, it may be less efficient in repairing damages caused by carcinogenic agents such as tobacco smoke or UV light.
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